Tumor-derived PTHrP acts on osteoblasts, altering the RANKL/Osteoprotegerin (OPG) ratio in the bone matrix, thereby promoting osteoclast maturation and causing metastatic bone destruction [49, 50]. Here, TNFRSF11B is linked to neoplasm.